InflaRx N.V

(NASDAQ:IFRX)

Latest On InflaRx N.V (IFRX):

Date/Time Type Description Signal Details
2023-05-11 20:55 ESTNewsInflaRx GAAP EPS of -€0.25N/A
2023-04-12 04:17 ESTNewsInflaRx starts public offering of ordinary stockN/A
2023-04-12 04:17 ESTNewsInflaRx prices $40M offeringN/A
2023-04-10 23:41 ESTNewsInflaRx Is Not Worth Chasing Following Emergency Use AuthorizationN/A
2023-04-04 15:54 ESTNewsInflaRx surges 60% on FDA authorization of COVID drug vilobelimabN/A
2023-03-22 12:33 ESTNewsInflaRx GAAP EPS of -€0.67N/A
2022-12-21 23:19 ESTNewsInflaRx stock surges as Staidson amends contract on COVID drug, $2.5M equity fundingN/A
2022-12-14 18:06 ESTNewsInflaRx: On Watch For A Buy During Tax Loss Selling SeasonN/A
2022-11-10 01:26 ESTNewsInflaRx GAAP EPS of -$0.18N/A
2022-09-29 11:16 ESTNewsInflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patientsN/A
2022-07-26 17:26 ESTNewsInflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patientsN/A
2022-07-06 23:38 ESTNewsInflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorderN/A
2022-06-29 18:18 ESTNewsInflaRx granted FDA Type B meeting to discuss submissions for COVID therapyN/A
2022-06-29 00:26 ESTNewsInflaRx stock soars 18% on vilobelimab getting FDA orphan drug status for skin disorderN/A
2022-05-24 20:08 ESTNewsInflaRx (IFRX) presents at H.C. Wainwright Global Investment Conference - SlideshowN/A
2022-05-12 18:45 ESTNewsInflaRx GAAP EPS of -€0.32N/A
2022-03-31 11:57 ESTNewsInflaRx vilobelimab fails to show statistical significance in severe COVID patients in trialN/A
2022-03-24 14:06 ESTNewsInflaRx GAAP EPS of -€1.10N/A
2022-02-28 12:08 ESTNewsInflaRx pauses phase 3 trial activities for vilobelimab, seeks clarity on FDA adviceN/A
2022-02-25 09:33 ESTNewsInflaRx (IFRX) Presents At Annual SVB Leerink Global Health ConferenceN/A
2022-01-15 16:25 ESTNewsInflarx (IFRX) Investor Presentation - SlideshowN/A
2021-12-29 20:58 ESTNewsOur First Look At InflaRxN/A
2021-11-16 02:36 ESTNewsInflaRx vasculitis candidate vilobelimab meets primary objective in phase 2 trialN/A
2021-11-08 13:30 ESTNewsInflaRx completes enrollment of vilobelimab phase III study in severe COVID-19N/A
2021-11-06 03:16 ESTNewsInflaRx EPS beats by $0.09N/A
2021-10-28 23:18 ESTNewsInflaRx climbs as Raymond James upgrades expecting price to quadrupleN/A
2021-10-27 19:59 ESTNewsInflaRx rises ~5% as vilobelimab helps reduce rare ulcers in phase 2a studyN/A
2021-10-19 12:52 ESTNewsInflaRx shares surge 29% after EUR 43.7M vilobelimab development grantN/A
2021-10-09 04:44 ESTNewsChemoCentryx propels InflaRx after FDA nod for vasculitis therapyN/A
2021-09-08 10:23 ESTNewsInflaRx provides development plan update for vilobelimab Hidradenitis Suppurativa trialN/A
2021-08-25 18:54 ESTNewsInflaRx And Vilobelimab In AAV: Avoiding Clinical Hard KnocksN/A
2021-08-11 02:37 ESTNewsInflaRx posts positive data from mid-stage vilobelimab skin disease studyN/A
2021-07-21 12:08 ESTNewsInflaRx initiates mid-stage vilobelimab skin cancer trialN/A
2021-04-15 21:07 ESTNewsInflaRx completes enrollment in mid-stage vilobelimab skin disease trialN/A
2021-03-25 15:37 ESTNewsInflaRx reports FY resultsN/A
2021-03-18 04:56 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.64 to $10.62.Neutral
2021-03-17 16:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.66 to $10.64.Neutral
2021-03-14 04:47 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.69 to $10.66.Neutral
2021-03-13 03:48 ESTAnalyst RatingThe Analyst Target Price has increased from $10.64 to $10.69.Buy
2021-03-12 07:54 ESTAnalyst RatingThe Analyst Target Price has increased from $9.61 to $10.64.Buy
2021-03-11 07:54 ESTAnalyst RatingThe Analyst Target Price has increased from $9.58 to $9.61.Buy
2021-03-10 03:58 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.64 to $9.58.Neutral
2021-03-09 03:53 ESTAnalyst RatingThe Analyst Target Price has increased from $9.62 to $9.64.Buy
2021-03-07 17:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.67 to $9.62.Neutral
2021-03-06 03:48 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.74 to $9.67.Neutral
2021-03-05 15:46 ESTAnalyst RatingThe Analyst Target Price has increased from $9.66 to $9.74.Buy
2021-03-05 07:59 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.69 to $9.66.Neutral
2021-03-04 07:51 ESTAnalyst RatingThe Analyst Target Price has increased from $9.66 to $9.69.Buy
2021-03-03 08:02 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.69 to $9.66.Neutral
2021-03-02 07:57 ESTAnalyst RatingThe Analyst Target Price has increased from $9.68 to $9.69.Buy

About InflaRx N.V (IFRX):

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

IFRX Quotes by TradingView

See Advanced Chart

General

  • Name InflaRx N.V
  • Symbol IFRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2017-11-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.inflarx.de
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.94
  • Enterprise Value EBITDA 0.02
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.33
  • Return on Assets -20%
  • Return on Equity -36%
  • Earnings Per Share -$2.08
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 194.64 million
  • Analyst Target Price $10.62
  • Book Value Per Share $7.20
View More

Share Statistics

  • Shares Outstanding 43.84 million
  • Shares Float 19.78 million
  • % Held by Insiders 2551%
  • % Held by Institutions 14.78%
  • Shares Short 429991
  • Shares Short Prior Month 467149
  • Short Ratio 0.97
  • Short % of Float 2%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 0.51
  • 52 Week High $9.7
  • 52 Week Low $2.98
  • 50 Day Moving Average 5.11
  • 200 Day Moving Average 4.77
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

InflaRx N.V (IFRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

InflaRx N.V (IFRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-10-29$N/A-$0.29-$0.3722.12%
2020-06-302020-07-30$N/A-$0.45-$0.42-6.56%
2020-03-312020-04-29$N/A-$0.57-$0.617.76%
2019-12-312019-12-31$N/A-$0.52-$0.6013.33%
2019-09-302019-11-07$N/A-$0.62-$0.59-5.73%
2019-06-302019-08-14$N/A-$0.66-$0.52-26.33%
2019-03-312019-05-23$N/A-$0.42-$0.5725.43%
2018-12-312019-03-28$N/A-$0.44-$0.38-16.22%
2018-09-302018-11-21$N/A-$0.34-$0.389.92%
2018-06-302018-08-09$N/A-$0.12-$0.3768.59%
2018-03-312018-05-17$N/A-$0.47-$0.34-36.79%
2017-12-312018-03-29$N/A-$0.46-$0.24-91.19%
2017-09-302017-12-21$N/A-$171.02-$203.2015.84%

InflaRx N.V (IFRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

InflaRx N.V (IFRX) Chart:

InflaRx N.V (IFRX) News:

Below you will find a list of latest news for InflaRx N.V (IFRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

InflaRx N.V (IFRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-05-162.50.05CALL1 58212.63FALSE0.050
2025-05-1650.7CALL0 10FALSE00
2025-05-167.50CALL0 00FALSE00
2025-05-162.50PUT0 0781.95TRUE00
2025-05-1650PUT0 0930.88TRUE00
2025-05-167.50PUT0 0842.38TRUE00
2025-06-202.50CALL0 0192.4FALSE00
2025-06-2050CALL0 00FALSE00
2025-06-207.50CALL0 00FALSE00
2025-06-202.50PUT0 0552.2TRUE00
2025-06-2050PUT0 0395.57TRUE00
2025-06-207.50PUT0 0557.6TRUE00
2025-07-182.50.1CALL0 454198.51FALSE00
2025-07-1850.3CALL0 714375.42FALSE00
2025-07-187.50.05CALL0 100414.42FALSE00
2025-07-182.50.74PUT0 297.29TRUE00
2025-07-1850PUT0 0752.38TRUE00
2025-07-187.50PUT0 0382.03TRUE00
2025-10-172.50.1CALL0 50FALSE00
2025-10-1750.1CALL0 300FALSE00
2025-10-177.50CALL0 00FALSE00
2025-10-172.50PUT0 0388.7TRUE00
2025-10-1750PUT0 0178.3TRUE00
2025-10-177.50PUT0 0290.75TRUE00

Latest IFRX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST30$1.285
Jun 13, 2022 7:59 PM EST53$1.285
Jun 13, 2022 7:59 PM EST47$1.285
Jun 13, 2022 7:59 PM EST119$1.285
Jun 13, 2022 7:59 PM EST14$1.285

InflaRx N.V (IFRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120015109/0001140361-20-015109-index.htm
2018-05-01UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1708688/000000000018013505/0000000000-18-013505-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1708688/000000000020006461/0000000000-20-006461-index.htm
2018-02-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000021545718004675/0000215457-18-004675-index.htm
2018-12-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000021545718007267/0000215457-18-007267-index.htm
2018-01-31SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000090266418000536/0000902664-18-000536-index.htm
2018-11-20SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000090266418004180/0000902664-18-004180-index.htm
2019-06-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000090266419002768/0000902664-19-002768-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000092963818000304/0000929638-18-000304-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000092963819000272/0000929638-19-000272-index.htm
2019-04-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000092963819000463/0000929638-19-000463-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000092963820000324/0000929638-20-000324-index.htm
2017-11-078-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1708688/000095010317010904/0000950103-17-010904-index.htm
2017-11-09POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1708688/000095010317011031/0000950103-17-011031-index.htm
2017-11-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1708688/000095010317011321/0000950103-17-011321-index.htm
2017-12-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010317012641/0000950103-17-012641-index.htm
2018-01-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318000262/0000950103-18-000262-index.htm
2018-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318000679/0000950103-18-000679-index.htm
2018-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318001570/0000950103-18-001570-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002047/0000950103-18-002047-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002052/0000950103-18-002052-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002054/0000950103-18-002054-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002055/0000950103-18-002055-index.htm
2018-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002056/0000950103-18-002056-index.htm
2018-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010318002086/0000950103-18-002086-index.htm
2018-03-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318003175/0000950103-18-003175-index.htm
2018-03-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318003975/0000950103-18-003975-index.htm
2018-03-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708688/000095010318003977/0000950103-18-003977-index.htm
2018-04-23DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005047/0000950103-18-005047-index.htm
2018-05-01DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005609/0000950103-18-005609-index.htm
2018-05-02F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005705/0000950103-18-005705-index.htm
2018-05-02DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005706/0000950103-18-005706-index.htm
2018-05-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005708/0000950103-18-005708-index.htm
2018-05-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1708688/000095010318005709/0000950103-18-005709-index.htm
2018-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318005917/0000950103-18-005917-index.htm
2018-05-07424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1708688/000095010318005944/0000950103-18-005944-index.htm
2018-05-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318006233/0000950103-18-006233-index.htm
2018-05-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318006284/0000950103-18-006284-index.htm
2018-06-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318007105/0000950103-18-007105-index.htm
2018-06-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318007856/0000950103-18-007856-index.htm
2018-08-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318009533/0000950103-18-009533-index.htm
2018-08-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318009867/0000950103-18-009867-index.htm
2018-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318010935/0000950103-18-010935-index.htm
2018-10-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318012617/0000950103-18-012617-index.htm
2018-11-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318013228/0000950103-18-013228-index.htm
2018-11-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318013637/0000950103-18-013637-index.htm
2018-12-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010318014809/0000950103-18-014809-index.htm
2019-01-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010319000154/0000950103-19-000154-index.htm
2019-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010319001752/0000950103-19-001752-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010319001881/0000950103-19-001881-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000095010319001882/0000950103-19-001882-index.htm
2019-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000095010319001993/0000950103-19-001993-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000101359419000111/0001013594-19-000111-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000110465920021759/0001104659-20-021759-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000110465920021822/0001104659-20-021822-index.htm
2019-03-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119005785/0001140361-19-005785-index.htm
2019-03-2820-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708688/000114036119005788/0001140361-19-005788-index.htm
2019-03-28F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1708688/000114036119005790/0001140361-19-005790-index.htm
2019-03-2920-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708688/000114036119006054/0001140361-19-006054-index.htm
2019-05-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119008351/0001140361-19-008351-index.htm
2019-05-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119008617/0001140361-19-008617-index.htm
2019-05-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119009045/0001140361-19-009045-index.htm
2019-05-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119009702/0001140361-19-009702-index.htm
2019-05-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119009755/0001140361-19-009755-index.htm
2019-06-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119010430/0001140361-19-010430-index.htm
2019-06-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119010950/0001140361-19-010950-index.htm
2019-06-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119011068/0001140361-19-011068-index.htm
2019-07-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119013125/0001140361-19-013125-index.htm
2019-08-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119015044/0001140361-19-015044-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119019970/0001140361-19-019970-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036119020589/0001140361-19-020589-index.htm
2020-01-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120000987/0001140361-20-000987-index.htm
2020-02-18SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708688/000114036120003446/0001140361-20-003446-index.htm
2020-02-18SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1708688/000114036120003448/0001140361-20-003448-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120004078/0001140361-20-004078-index.htm
2020-03-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120004516/0001140361-20-004516-index.htm
2020-04-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120007597/0001140361-20-007597-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120008420/0001140361-20-008420-index.htm
2020-04-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120010060/0001140361-20-010060-index.htm
2020-04-2920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1708688/000114036120010155/0001140361-20-010155-index.htm
2020-05-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120012114/0001140361-20-012114-index.htm
2020-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120014021/0001140361-20-014021-index.htm
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120015109/0001140361-20-015109-index.htm
2020-07-08F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1708688/000114036120015637/0001140361-20-015637-index.htm
2020-07-16F-3/ARegistration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1708688/000114036120016134/0001140361-20-016134-index.htm
2020-07-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1708688/000114036120016136/0001140361-20-016136-index.htm
2020-07-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120016197/0001140361-20-016197-index.htm
2020-07-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120016366/0001140361-20-016366-index.htm
2020-07-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1708688/000114036120016369/0001140361-20-016369-index.htm
2020-07-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120016440/0001140361-20-016440-index.htm
2020-07-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120017008/0001140361-20-017008-index.htm
2020-07-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1708688/000114036120017017/0001140361-20-017017-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120017612/0001140361-20-017612-index.htm
2020-09-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120020303/0001140361-20-020303-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120020689/0001140361-20-020689-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000114036120024043/0001140361-20-024043-index.htm
2017-12-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420417063135/0001144204-17-063135-index.htm
2018-04-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420418022753/0001144204-18-022753-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420419008082/0001144204-19-008082-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420419008283/0001144204-19-008283-index.htm
2019-04-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420419019101/0001144204-19-019101-index.htm
2019-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000114420419034319/0001144204-19-034319-index.htm
2017-11-08424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1708688/000119312517337427/0001193125-17-337427-index.htm
2017-11-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000119312517345585/0001193125-17-345585-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000119312519039744/0001193125-19-039744-index.htm
2019-02-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1708688/000119312519052970/0001193125-19-052970-index.htm
2019-03-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000119312519082869/0001193125-19-082869-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1708688/000119312520036484/0001193125-20-036484-index.htm
2017-11-07EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1708688/999999999517002900/9999999995-17-002900-index.htm
2018-05-03EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1708688/999999999518001136/9999999995-18-001136-index.htm
2020-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1708688/999999999520001851/9999999995-20-001851-index.htm
2017-11-08CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1708688/999999999717009748/9999999997-17-009748-index.htm
2017-11-07CERTNASCertification by the Nasdaq Stock Market approving securities for listinghttps://www.sec.gov/Archives/edgar/data/1708688/999999999717009817/9999999997-17-009817-index.htm